LOGO
LOGO

Will Incannex Wake Up Or Slip Into Deep Slumber? Sleep Apnea Trial Data May Decide Its Fate

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company, is approaching a data readout for its lead drug candidate that could mark a pivotal moment in its development.

The company is developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. Its clinical programs include IHL-42X, IHL-675A, and PSX-001.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.